Skip to main content
Clinical Trials/KCT0009301
KCT0009301Active, not recruitingUnknown

A 8 week, Randomized, Double-Blind, Crossover, Placebo-Controlled Trial for the Evaluation of the Efficacy and Safety of A2 Milk on Digestion

Seoul Dairy co-op.0 sites40 target enrollmentStarted: TBDLast updated:

Trial Snapshot

Phase
Unknown
Status
Active, not recruiting
Sponsor
Enrollment
40

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
20(Year) to 70(Year) (—)
Sex
All

Inclusion Criteria

  • 1) Between 20 to 70 years of age
  • 2) Participants who are experiencing digestive symptoms (bloating, gas, heaviness, abdominal pain, flatulence, borborygmus, bowel urgency) following milk consumption on Visit 1 with each score on the digestive discomfort symptom survey being 2 points or less. (Individuals who have indicated 0 in all symptoms or 3 in at least one symptom will be excluded.)
  • 3) Those who have agreed to participate and given written consent through the Informed Consent Form prior to the study

Exclusion Criteria

  • 1) Currently undergoing treatment for severe cardiovascular, immune, respiratory, gastrointestinal/hepatic and biliary, renal and urinary, neurological, musculoskeletal, mental, infectious, metabolic diseases, and malignancies
  • 2) Diagnosed with or has a history of gastrointestinal diseases (irritable bowel syndrome, colitis, ulcerative colitis, abdominal diseases etc.), or has undergone gastrointestinal surgery
  • 3) Individuals with severe lactose intolerance
  • 4) History of bowel obstruction
  • 5) Alcohol addiction or substance abuse
  • 6) Hospitalized within the last 3 months of Visit 1
  • 7) Has taken medication affecting body weight {anti-obesity drugs (appetite suppressants, fat absorption inhibitors, Glucagon-like peptide-1 (GLP-1) receptor agonists etc.), psychiatric drugs such as antidepressants and antipsychotics, diuretics, contraceptives, steroids, female hormones, thyroid hormones} within the last 3 months of Visit 1
  • 8) Has taken immunosuppressive drugs or anti-inflammatory drugs within the last month (30 days) of Visit 1
  • 9) Administered antibiotics or laxatives within the last 2 weeks of Visit 2
  • 10) Has taken prokinetics (Serotonin type 4 (5-HT4) Agonist, D2 Antagonists, Cholinergic Agonists etc.), laxatives {fiber supplements (Psyllium, Methylcellulose etc.), stool softeners, osmotic laxatives (Sorbitol, Lactulose etc.), stimulant laxatives (Bisacodyl, Anthraquinone etc.)}
  • 11) Pregnant, breastfeeding, or planning to become pregnant during the study period
  • 12) Allergic to dairy products
  • 13) Participated in another interventional clinical trial (including human trials) within the last 3 months of Visit 1, or planning to participate in another interventional clinical trial (including human trials) after the start of this study
  • 14) Individuals deemed inappropriate for the study by the investigator

Investigators

Sponsor
Seoul Dairy co-op.

Similar Trials

Recruiting
Not Applicable
A 8 week, Single-center, Randomized, Double-Blind, Placebo-Controlled Clinical Trial for the Evaluation of the Efficacy and Safety of SPB-201on gastric functional
KCT0009505Sungkyunbiotech100
Completed
Unknown
A 8 week, Multi-center, Randomized, Double-Blind, Placebo-Controlled Human Study for the Evaluation of the Efficacy and Safety of PMEC on Gingival health
KCT0008940MedibioLAB100
Active, not recruiting
Not Applicable
An eight week, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of the combination of aliskiren / valsartan / HCTZ (300/320/25 mg), compared to the combinations of aliskiren / HCTZ (300/25 mg) and valsartan / HCTZ (320/25 mg) in patients with essential hypertension not adequately responsive to HCTZ 25 mgHypertension
EUCTR2005-002635-27-ESovartis Farmacéutuca, S.A.624
Active, not recruiting
Not Applicable
An eight week, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of the combination of aliskiren / valsartan / HCTZ (300/320/25 mg), compared to the combinations of aliskiren / HCTZ (300/25 mg) and valsartan / HCTZ (320/25 mg) in patients with essential hypertension not adequately responsive to HCTZ 25 mgHypertension
EUCTR2005-002635-27-DEovartis Pharma Services AG624
Active, not recruiting
Not Applicable
An 8-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Flexible Dose Study of Pregabalin (300-600 mg/day) and Venlafaxine XR (75-225 mg/day) for the Acute Treatment of DSM-IV Generalized Anxiety Disorder in Outpatients.Generalized anxiety disorder.MedDRA version: 6.1Level: PTClassification code 10002855
EUCTR2004-001500-13-ITPFIZER